靶向寨卡病毒嵌合抗原的理性设计与制备及其在小鼠中诱导中和抗体
本研究基于寨卡病毒抗原序列、细菌载体和连接子设计了多表位蛋白rpZDIII,在大肠杆菌中表达并纯化复性,每升发酵液获得11 mg纯可溶性重组蛋白。小鼠皮下三剂次免疫后诱导血清IgG和IgM应答,血清显示对寨卡病毒的中和活性,作者认为rpZDIII是开发理性设计多表位寨卡疫苗的有前景免疫原。
要点
- 设计的多表位嵌合抗原rpZDIII在大肠杆菌中表达,纯化复性后产量为每升发酵液11 mg纯可溶性重组蛋白。
- 小鼠皮下三剂次免疫rpZDIII后诱导血清IgG和IgM应答。
- rpZDIII免疫小鼠血清显示对寨卡病毒的中和活性。
核心结论
- 作者认为rpZDIII是开发理性设计多表位寨卡疫苗的有前景免疫原,并称其临床前评价的完成有保障。
研究设计与样本
- 基于一系列寨卡病毒抗原序列、细菌载体和连接子设计多表位蛋白rpZDIII,用AlphaFold 2服务器分析预测的三维结构,在大肠杆菌中生产并从包涵体纯化,经溶解和复性处理。
主要发现
- rpZDIII的产量为每升发酵液11 mg纯可溶性重组蛋白。
- 小鼠皮下三剂次免疫rpZDIII后诱导血清IgG和IgM应答。
- rpZDIII免疫小鼠的血清显示对寨卡病毒的中和活性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Zika virus (ZIKV) is considered a public health problem worldwide due to its association with the development of microcephaly and the Guillain-Barré syndrome. Currently, there is no specific treatment or vaccine approved to combat this disease, and thus, developing safe and effective vaccines is a relevant goal. In this study, a multi-epitope protein called rpZDIII was designed based on a series of ZIKV antigenic sequences, a bacterial carrier, and linkers. The analysis of the predicted 3D structure of the rpZDIII chimeric antigen was performed on the AlphaFold 2 server, and it was produced in E. coli and purified from inclusion bodies, followed by solubilization and refolding processes. The yield achieved for rpZDIII was 11 mg/L in terms of pure soluble recombinant protein per liter of fermentation. rpZDIII was deemed immunogenic since it induced serum IgG and IgM responses in mice upon subcutaneous immunization in a three-dose scheme. Moreover, sera from mice immunized with rpZDIII showed neutralizing activity against ZIKV. Therefore, this study reveals rpZDIII as a promising immunogen for the development of a rationally designed multi-epitope vaccine against ZIKV, and completion of its preclinical evaluation is guaranteed.
引用
- Miranda-López A, González-Ortega O, Govea-Alonso DO, et al. Rational design and production of a chimeric antigen targeting Zika virus that induces neutralizing antibodies in mice. Vaccine. 2024. PMID: 38749821. doi:10.1016/j.vaccine.2024.04.080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。